EGFR and breast carcinoma: High expression levels of KLF5 are a determinant of resistance to cisplatin in ovarian and breast cancers (Dong et al., 2013; Li et al., 2017) and corresponded with enhanced EGFR signaling in both colorectal cell lines (Fig. 2C,E).